Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156697 | 0.95 | KDM4E (0.47) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL3740930 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL1826965 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL2028355 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL5357939 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL8015861 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL451183 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL2024342 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL2536987 | 0.94 | KDM4E (0.49) | ALOX5CYP2C9HPGDCYP2C19HTT | |
| SCHEMBL5638282 | 0.91 | CYP2C9 (0.46) | CYP2C9HPGDCYP2C19HTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6323275-B2 | HAVING A LOWERED ADHESION TO THE SKIN | TOAGOSEI CO., LTD. (JP) | 2001-11-27 | — | — | US | claimed |
| JP-3291201-A | — | — | None | — | — | JP | disclosed |
| US-20040030093-A1 | Metal catalyst for ring-opening polymerization of heterocyclic compound | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1340780-A1 | METAL CATALYST FOR RING-OPENING POLYMERIZATION OF HETEROCYCLIC COMPOUND | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6323275-B2 | HAVING A LOWERED ADHESION TO THE SKIN | TOAGOSEI CO., LTD. (JP) | 2001-11-27 | — | — | US | disclosed |
| US-20010004655-A1 | CYANOACRYLATE ADHESIVE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2001-06-21 | — | — | US | disclosed |
| EP-0975768-A2 | PHENOLIC ACID ESTERASE AND USE THEREOF | THE BABRAHAM INSTITUTE (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046768-A2 | PHENOLIC ACID ESTERASE AND USE THEREOF | THE BABRAHAM INSTITUTE (GB) | 1998-10-22 | — | — | WO | disclosed |
| JP-H03291201-A | HERBICIDE | TEIJIN LTD | 1991-12-20 | — | — | JP | disclosed |
| EP-0382990-A1 | Strains of bacillus thuringiensis | PLANT GENETIC SYSTEMS, N.V. (BE) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030093-A1 | Metal catalyst for ring-opening polymerization of heterocyclic compound | MAX, PCNA, POLM | ALOX5 928/4885CYP2C9 427/4885HPGD 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.